Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In an ongoing Phase I trial in 18 evaluable patients who received 0.015-0.06 mg/m 2/day of MT103, there were
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury